Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6005 in Advanced Malignant Tumors
NCT06958679Phase 1Recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SYS6005 in solid tumor and B cell malignancies, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoints: Incidence of Dose Limiting Toxicities, Recommended Phase 2 Dose up to 6 months and 3 more. Started Apr 2025; status: recruiting.
02
Drugs
SYS6005
03
Conditions
solid tumorB cell malignancies
Beyond the preview
Go deeper on NCT06958679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06958679.